A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Inclusion Criteria: * Evidence of qualifying vessel (carotid or aortic) plaque inflammation * Documented atherosclerotic vascular disease clinically stable for at least 3 months prior to screening or type 2 diabetes mellitus with elevated cardiovascular risk * Use of a stable dose of statin therapy for at least 6 weeks prior to screening. Patients must be capable of maintaining statin therapy at a current dose level from screening until the last follow-up visit. * For patients taking angiotensin-converting enzyme (ACE) inhibitors (ACE-I) or angiotensin-receptor blockers (ARBs), non-statin lipid-modifying therapy, thiazolidinediones, inhaled steroids, or leukotriene modifying agents, use of a stable dose for at least 6 weeks prior to screening and capable of continuing with that dose for the duration of the study Exclusion Criteria: * Occurrence of a cardiovascular event \< 6 months prior to screening * Pregnant, planning to become pregnant during the study, or breastfeeding * Clinically significant abnormal laboratory values or abnormal ECG or vital signs * History of anaphylactic reactions * Newly discovered Type 2 diabetes mellitus (T2DM) (prior to study entry) or medical treatment for T2DM started \< 3 months prior to study entry * Use of insulin, corticosteroids (oral, rectal, or injectable), or other immunosuppressive medications * Current or recent (within 4 weeks prior to screening) infection, including signs, symptoms or serology of any infection, including HIV, hepatitis B or C * Impaired renal function * History of malignancy within 2 years prior to screening * Current life-threatening condition other than vascular disease that may prevent a patient from completing the study * Use of an investigational drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study medication * Exposure to substantial radiation within 12 months prior to screening